Skip to main content

Table 2 Baseline characteristics of primary prevention patients experienced VA vs. secondary prevention patients

From: Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients

Baseline characteristics

Before matching

After matching

Primary Prevention experienced VA(n = 210)

Secondary Prevention (n = 364)

P-value

Primary Prevention experienced VA(n = 173)

Secondary Prevention (n = 173)

P-value

Male

166 (79.0%)

259 (71.2%)

0.038

135 (78.0%)

126 (72.8%)

0.318

Age(years)

62.72 ± 11.83

58.30 ± 13.93

0.001

62.58 ± 11.77

64.00 ± 12.80

0.115

Ischemic heart disease

57 (27.1%)

111 (30.5%)

0.446

47 (27.2%)

61 (35.3%)

0.131

Hypertension

70 (33.3%)

104 (28.6%)

0.258

53 (30.6%)

54 (31.2%)

0.907

Diabetes

28 (13.3%)

34 (9.3%)

0.162

21 (12.1%)

21 (12.1%)

1.000

Stroke

4 (1.9%)

7 (1.9%)

1.000

3 (1.7%)

4 (2.3%)

1.000

Atrial fibrillation

26 (12.4%)

33 (9.1%)

0.253

24 (13.9%)

21 (12.1%)

0.632

LVEF (%)

33.13 ± 10.64

43.18 ± 12.00

<0.001

34.73 ± 10.83

36.33 ± 11.00

0.116

LVEDD (mm)

64.68 ± 12.94

57.83 ± 10.74

<0.001

63.84 ± 13.25

62.87 ± 10.80

0.707

NYHA class III-IV

129 (61.4%)

117 (32.1%)

<0.001

97 (56.1%)

95 (54.9%)

0.829

Beta-blockers

129 (61.4%)

210 (57.7%)

0.428

107 (61.8%)

99 (57.2%)

0.381

ACEI/ARB

88 (43.8%)

92 (24.2%)

<0.001

68 (39.3%)

60 (34.7%)

0.373

Diuretics

77 (36.7%)

69 (19.0%)

<0.001

56 (32.4%)

48 (27.7%)

0.348

Amiodarone

47 (22.4%)

129 (35.4%)

0.001

45 (26.0%)

52 (30.1%)

0.404

  1. Abbreviations: VA Ventricular arrhythmia, LVEF Left ventricular Ejection fraction, LVEDD Left ventricular end-diastolic diameter, NYHA class New York Heart Association class, ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker